Insider Buying: Eyepoint Pharmaceuticals Inc (EYPT) Director Buys 40,000 Shares of Stock

Eyepoint Pharmaceuticals Inc (NASDAQ:EYPT) Director John B. Landis bought 40,000 shares of the business’s stock in a transaction on Monday, May 13th. The shares were acquired at an average cost of $1.74 per share, for a total transaction of $69,600.00. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Shares of Eyepoint Pharmaceuticals stock traded down $0.02 on Thursday, reaching $1.81. 5,061 shares of the company were exchanged, compared to its average volume of 398,239. The firm has a market capitalization of $189.93 million, a PE ratio of -3.12 and a beta of 1.89. The company has a quick ratio of 2.57, a current ratio of 2.57 and a debt-to-equity ratio of 0.37. Eyepoint Pharmaceuticals Inc has a fifty-two week low of $1.24 and a fifty-two week high of $3.94.

Eyepoint Pharmaceuticals (NASDAQ:EYPT) last announced its earnings results on Wednesday, May 8th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.03). The company had revenue of $2.01 million for the quarter, compared to analyst estimates of $3.70 million. Eyepoint Pharmaceuticals had a negative return on equity of 174.26% and a negative net margin of 1,739.81%. Analysts expect that Eyepoint Pharmaceuticals Inc will post -0.4 EPS for the current year.

Institutional investors have recently made changes to their positions in the company. Virtu Financial LLC purchased a new position in shares of Eyepoint Pharmaceuticals during the fourth quarter valued at $31,000. Arcus Capital Partners LLC acquired a new stake in shares of Eyepoint Pharmaceuticals in the first quarter worth about $45,000. Private Advisor Group LLC acquired a new stake in shares of Eyepoint Pharmaceuticals in the first quarter worth about $60,000. Jefferies Group LLC acquired a new stake in shares of Eyepoint Pharmaceuticals in the first quarter worth about $94,000. Finally, Bank of New York Mellon Corp lifted its position in shares of Eyepoint Pharmaceuticals by 78.5% in the fourth quarter. Bank of New York Mellon Corp now owns 51,501 shares of the company’s stock worth $97,000 after buying an additional 22,645 shares during the last quarter. 51.93% of the stock is currently owned by institutional investors.

Several analysts have weighed in on the company. Zacks Investment Research raised Eyepoint Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday. HC Wainwright reissued a “buy” rating and issued a $4.50 price objective on shares of Eyepoint Pharmaceuticals in a research note on Thursday, May 9th. Finally, ValuEngine downgraded Eyepoint Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, March 21st.

COPYRIGHT VIOLATION WARNING: “Insider Buying: Eyepoint Pharmaceuticals Inc (EYPT) Director Buys 40,000 Shares of Stock” was published by Baseball Daily News and is the sole property of of Baseball Daily News. If you are accessing this news story on another site, it was copied illegally and republished in violation of United States & international copyright law. The original version of this news story can be viewed at https://www.baseballdailydigest.com/news/2019/05/16/insider-buying-eyepoint-pharmaceuticals-inc-eypt-director-buys-40000-shares-of-stock.html.

About Eyepoint Pharmaceuticals

EyePoint Pharmaceuticals, Inc, a specialty biopharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States and Europe. It provides ILUVIEN for the treatment of diabetic macular edema; YUTIQ, a non-erodible fluocinolone acetonide insert for the treatment of non-infectious posterior uveitis (NIPU) that is in the Phase III clinical trials; and Retisert (fluocinolone acetonide intravitreal implant), a sustained-release implant for the treatment of posterior segment uveitis.

Featured Story: Price-Sales Ratio

Receive News & Ratings for Eyepoint Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eyepoint Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.